2006 OPEN FORUM Abstracts
ASSOCIATIONS BETWEEN INSULIN RECEPTOR SUBSTRATE-1 G972R POLYMORPHISM AND NON-SMALL CELL LUNG CANCER RISK
Chang Youl Lee1, Chul Min Ahn1,2, Yoon Soo Chang1,
Hyung Jung Kim1,2, Se Kyu Kim1,2,3,4, Dong Hwan Shin5,
Joon Chang1,2, Sung Kyu Kim1,2
Department of Internal Medicine1, The Institute of Chest Diseases2, Brain Korea 21 Project for Medical Sciences3, Cancer Metastasis Research Center4 and Pathology5, Yonsei University College of Medicine, Seoul, Korea
Background; Insulin receptor substrate-1 (IRS-1) is the primary docking molecule for the insulin-like growth factor (IGF) receptor (IGFR) and required for activation of the phosphoinositol-3-kinase (PI3K) pathway, which regulates IGF mediated survival, enhancement of cellular motility, and anti-apoptosis. Therefore, we attempted to ascertain whether the genetic variations in IRS-1 may affect an individual's risk of non-small cell lung cancer (NSCLC).
Materials and Methods; Genomic DNAs from 111 patients who were diagnosed as NSCLC and those from age, gender and smoking status matched control subjects were analyzed by PCR followed by restriction fragment length polymorphism (RFLP) for determination of IRS-1 G972R polymorphism.
Results; The frequencies of each polymorphic variation in the control population were as follows: GG= 106 (97.2%) and GR = 3 (2.8%). In the NSCLC subjects, the genotypic frequencies were as follows: GG = 108 (97.3%) and GR = 3 (2.7 %). We could not find statistically significant differences in the genotypic distribution between the NSCLC and the control subjects (p =0.499, Fisher's Exact test). The relative risk of NSCLC associated with the IRS-1 G972R polymorphic variation was 1.028 (95% CI; 0.63-9.90). No differences between polymorphic subtypes existed with regard to the histologic subtypes.
Conclusion; No noteworthy differenced in the frequency of IRS-1 G972R polymorphism were observed suggesting that IRS-1 G972R polymorphism may not be a NSCLC risk in our populations.